Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial

医学 内科学 头孢呋辛 人口 甲氧苄啶 梅西利南 阿莫西林 降级 抗生素 环境卫生 微生物学 生物 生物化学 化学 大肠杆菌 肠杆菌科 基因
作者
Luis Eduardo López-Cortés,Mercedes Delgado-Valverde,Elisa Moreno-Mellado,Josune Goikoetxea Aguirre,Laura Guío Carrión,María José Blanco Vidal,Leyre Mónica López Soria,Pérez Rodríguez,Lucía Martínez Lamas,Francisco Arnaíz de las Revillas,Carlos Armiñanzas,Carlos Ruiz de Alegría Puig,Patricia Jiménez Aguilar,María del Carmen Martínez-Rubio,Carmen Sáez-Béjar,Carmen de las Cuevas,Andrés Martín-Aspas,Fátima Galán‐Sánchez,José Ramón Yuste,José Leiva
出处
期刊:Lancet Infectious Diseases [Elsevier BV]
卷期号:24 (4): 375-385 被引量:32
标识
DOI:10.1016/s1473-3099(23)00686-2
摘要

Background De-escalation from broad-spectrum to narrow-spectrum antibiotics is considered an important measure to reduce the selective pressure of antibiotics, but a scarcity of adequate evidence is a barrier to its implementation. We aimed to determine whether de-escalation from an antipseudomonal β-lactam to a narrower-spectrum drug was non-inferior to continuing the antipseudomonal drug in patients with Enterobacterales bacteraemia. Methods An open-label, pragmatic, randomised trial was performed in 21 Spanish hospitals. Patients with bacteraemia caused by Enterobacterales susceptible to one of the de-escalation options and treated empirically with an antipseudomonal β-lactam were eligible. Patients were randomly assigned (1:1; stratified by urinary source) to de-escalate to ampicillin, trimethoprim–sulfamethoxazole (urinary tract infections only), cefuroxime, cefotaxime or ceftriaxone, amoxicillin–clavulanic acid, ciprofloxacin, or ertapenem in that order according to susceptibility (de-escalation group), or to continue with the empiric antipseudomonal β-lactam (control group). Oral switching was allowed in both groups. The primary outcome was clinical cure 3–5 days after end of treatment in the modified intention-to-treat (mITT) population, formed of patients who received at least one dose of study drug. Safety was assessed in all participants. Non-inferiority was declared when the lower bound of the 95% CI of the absolute difference in cure rate was above the –10% non-inferiority margin. This trial is registered with EudraCT (2015-004219-19) and ClinicalTrials.gov (NCT02795949) and is complete. Findings 2030 patients were screened between Oct 5, 2016, and Jan 23, 2020, of whom 171 were randomly assigned to the de-escalation group and 173 to the control group. 164 (50%) patients in the de-escalation group and 167 (50%) in the control group were included in the mITT population. 148 (90%) patients in the de-escalation group and 148 (89%) in the control group had clinical cure (risk difference 1·6 percentage points, 95% CI –5·0 to 8·2). The number of adverse events reported was 219 in the de-escalation group and 175 in the control group, of these, 53 (24%) in the de-escalation group and 56 (32%) in the control group were considered severe. Seven (5%) of 164 patients in the de-escalation group and nine (6%) of 167 patients in the control group died during the 60-day follow-up. There were no treatment-related deaths. Interpretation De-escalation from an antipseudomonal β-lactam in Enterobacterales bacteraemia following a predefined rule was non-inferior to continuing the empiric antipseudomonal drug. These results support de-escalation in this setting. Funding Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases; Spanish Clinical Research and Clinical Trials Platform, co-financed by the EU; European Development Regional Fund "A way to achieve Europe", Operative Program Intelligence Growth 2014–2020.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
赵梦杰完成签到,获得积分10
2秒前
wanci的应助被科研通管家采纳,获得10
2秒前
3秒前
DW的应助被科研通管家采纳,获得10
3秒前
Hello的应助被zr采纳,获得10
3秒前
syvshc的应助被科研通管家采纳,获得10
3秒前
fantasy的应助被科研通管家采纳,获得10
3秒前
小马甲的应助被科研通管家采纳,获得10
3秒前
丘比特的应助被科研通管家采纳,获得10
3秒前
3秒前
molihuakai的应助被科研通管家采纳,获得10
3秒前
3秒前
在水一方的应助被科研通管家采纳,获得10
4秒前
molihuakai的应助被科研通管家采纳,获得10
4秒前
完美世界的应助被科研通管家采纳,获得10
4秒前
今后的应助被科研通管家采纳,获得10
4秒前
Owen的应助被科研通管家采纳,获得10
4秒前
酷波er的应助被科研通管家采纳,获得10
4秒前
清秀语蝶的应助被科研通管家采纳,获得30
4秒前
852的应助被科研通管家采纳,获得10
4秒前
超人Steiner完成签到 ,获得积分10
4秒前
英俊的铭的应助被科研通管家采纳,获得10
5秒前
5秒前
orixero的应助被科研通管家采纳,获得10
5秒前
NexusExplorer的应助被科研通管家采纳,获得10
5秒前
zzzq完成签到,获得积分10
5秒前
CC发布了新的文献求助10
5秒前
CodeCraft的应助被科研通管家采纳,获得10
5秒前
Maestro_S的应助被科研通管家采纳,获得10
5秒前
Akim的应助被科研通管家采纳,获得10
5秒前
李爱国的应助被科研通管家采纳,获得10
5秒前
科研菜鸟发布了新的文献求助10
5秒前
orixero的应助被科研通管家采纳,获得10
6秒前
个性的夜白完成签到,获得积分10
6秒前
wanci的应助被科研通管家采纳,获得10
6秒前
6秒前
6秒前
6秒前
天天快乐的应助被科研通管家采纳,获得10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186629
求助须知:如何正确求助?哪些是违规求助? 9574913
关于积分的说明 21838832
捐赠科研通 7784206
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559183
邀请新用户注册赠送积分活动 2481582